Emil Gregersen

Emil Gregersen

Auto-generated profile, based on publicly available information

Emil Gregersen

Danish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2018 in EMBO Reports
Verified
Journal Article
Open access
PDF file
CBCristine Betzer
Cristine Betzer
LLLouise Berkhoudt Lassen
Louise Berkhoudt Lassen
Anders OlsenAnders Olsen
Anders Olsen
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
LRLasse Reimer
Lasse Reimer
PJPoul Henning Jensen
Poul Henning Jensen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

26 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLouise Berkhoudt Lassen
Louise Berkhoudt Lassen
EGEmil Gregersen
Emil Gregersen
AIAnne Kathrine Isager
Anne Kathrine Isager
CBCristine Betzer
Cristine Betzer
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
PJPoul Henning Jensen
Poul Henning Jensen
Soluble aggregates of α-synuclein, so-called oligomers, are hypothesized to act as neurotoxic species in Parkinson’s disease, Lewy body dementia and multiple systems atrophy, but specific tools to detect these aggregated species are only slowly appearing. We have developed an α-synuclein oligomer ELISA that allows us to detect and compare α-synuclein oligomer levels in different in vivo and in vitro experiments. The ELISA is based on commercially available antibodies and the epitope of the capture antibody MJF14-6-4-2 is folding- and aggregate-dependent and not present on monomers.

12 June 2021 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
LVLaura M. Vecchio
Laura M. Vecchio
PSPatricia Sullivan
Patricia Sullivan
ADAmy R. Dunn
Amy R. Dunn
MBMarie Kristel Bermejo
Marie Kristel Bermejo
RFRong Fu
Rong Fu
ASAli Salahpour
Ali Salahpour
In Parkinson's disease, dopamine‐containing nigrostriatal neurons undergo profound degeneration. Tyrosine hydroxylase (TH) is the rate‐limiting enzyme in dopamine biosynthesis. TH increases in vitro formation of reactive oxygen species, and previous animal studies have reported links between cytosolic dopamine build‐up and oxidative stress. To examine effects of increased TH activity in catecholaminergic neurons in vivo, we generated TH‐over‐expressing mice (TH‐HI) using a BAC‐transgenic approach that results in over‐expression of TH with endogenous patterns of expression. The transgenic mice were characterized by western blot, qPCR, and immunohistochemistry. Tissue contents of dopamine, its metabolites, and markers of oxidative stress were evaluated. TH‐HI mice had a 3‐fold increase in total and phosphorylated TH levels and an increased rate of dopamine synthesis. Coincident with elevated dopamine turnover, TH‐HI mice showed increased striatal production of H2O2 and reduced glutathione levels. In addition, TH‐HI mice had elevated striatal levels of the neurotoxic dopamine metabolites 3,4‐dihydroxyphenylacetaldehyde and 5‐S‐cysteinyl‐dopamine and were more susceptible than wild‐type mice to the effects of amphetamine and methamphetamine. These results demonstrate that increased TH alone is sufficient to produce oxidative stress in vivo, build up autotoxic dopamine metabolites, and augment toxicity. image

6 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SESara Elfarrash
Sara Elfarrash
NJNanna Møller Jensen
Nanna Møller Jensen
Nelson FerreiraNelson Ferreira
Nelson Ferreira
SSSissel Ida Schmidt
Sissel Ida Schmidt
EGEmil Gregersen
Emil Gregersen
PJPoul Henning Jensen
Poul Henning Jensen
Accumulation of aggregated alpha-synuclein (α-syn) is believed to play a pivotal role in the pathophysiology of Parkinson’s disease (PD) and other synucleinopathies. As a key constituent of Lewy pathology, more than 90% of α-syn in Lewy bodies is phosphorylated at serine-129 (pS129) and hence, it is used extensively as a marker for α-syn pathology. However, the exact role of pS129 remains controversial and the kinase(s) responsible for the phosphorylation have yet to be determined. In this study, we investigated the effect of Polo-like kinase 2 (PLK2) inhibition on formation of pS129 using an ex vivo organotypic brain slice model of synucleinopathy. Our data demonstrated that PLK2 inhibition has no effect on α-syn aggregation, pS129 or inter-neuronal spreading of the aggregated α-syn seen in the organotypic slices. Instead, PLK2 inhibition reduced the soluble pS129 level in the nuclei. The same finding was replicated in an in vivo mouse model of templated α-syn aggregation and in human dopaminergic neurons, suggesting that PLK2 is more likely to be involved in S129-phosphorylation of the soluble physiological fraction of α-syn. We also demonstrated that reduction of nuclear pS129 following PLK2 inhibition for a short time before sample collection improves the signal-to-noise ratio when quantifying pS129 aggregate pathology.

11 October 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HRHarm Ruesink
Harm Ruesink
LRLasse Reimer
Lasse Reimer
EGEmil Gregersen
Emil Gregersen
AMArne Moeller
Arne Moeller
CBCristine Betzer
Cristine Betzer
PJPoul Henning Jensen
Poul Henning Jensen
The group of neurodegenerative diseases, Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) all exhibit inclusions containing amyloid-type α-synuclein (α-syn) aggregates within degenerating brain cells. α-syn also exists as soluble oligomeric species that are hypothesized to represent intermediates between its native and aggregated states. These oligomers are present in brain extracts from patients suffering from synucleinopathies and hold great potential as biomarkers. Although easily prepared in vitro, oligomers are metastable and dissociate over time, thereby complicating α-syn oligomer research. Using the small amine-reactive cross-linker, formaldehyde (FA), we successfully stabilized α-syn oligomers without affecting their size, overall structure or antigenicity towards aggregate-conformation specific α-syn antibodies FILA and MJFR-14-6-4-2. Further, cross-linked α-syn oligomers show resistance towards denaturant like urea and SDS treatment and remain fully functional as internal standard in an aggregation-specific enzyme-linked immunosorbent assay (ELISA) despite prior incubation with urea. We propose that FA cross-linked α-syn oligomers could serve as important calibrators to facilitate comparative and standardized α-syn biomarker studies going forward.

2 November 2023 in The EMBO Journal
Verified
Journal Article
Open access
AKAntoni Kowalski
Antoni Kowalski
CBCristine Betzer
Cristine Betzer
SLSigrid Thirup Larsen
Sigrid Thirup Larsen
EGEmil Gregersen
Emil Gregersen
ENEstella Anne Newcombe
Estella Anne Newcombe
PNPoul Nissen
Poul Nissen
Alpha‐synuclein (aSN) is a membrane‐associated and intrinsically disordered protein, well known for pathological aggregation in neurodegeneration. However, the physiological function of aSN is disputed. Pull‐down experiments have pointed to plasma membrane Ca 2+ ‐ATPase (PMCA) as a potential interaction partner. From proximity ligation assays, we find that aSN and PMCA colocalize at neuronal synapses, and we show that calcium expulsion is activated by aSN and PMCA. We further show that soluble, monomeric aSN activates PMCA at par with calmodulin, but independent of the autoinhibitory domain of PMCA, and highly dependent on acidic phospholipids and membrane‐anchoring properties of aSN. On PMCA, the key site is mapped to the acidic lipid‐binding site, located within a disordered PMCA‐specific loop connecting the cytosolic A domain and transmembrane segment 3. Our studies point toward a novel physiological role of monomeric aSN as a stimulator of calcium clearance in neurons through activation of PMCA.